Abstract: The present disclosure relates to various aspects of a procedure for reducing the carbon dioxide content in blood during the treatment of patients. A first aspect of the present disclosure relates to a buffer solution for use in reducing the carbon dioxide content in the blood when treating a patient suffering from pulmonary insufficiency or the complete failure of lung function, wherein the fluid is in gas exchange with a portion of the patient's blood conducted through an extracorporeal circuit. The first aspect of the present disclosure further relates to an apparatus for the extracorporeal reduction of the carbon dioxide content in the blood using said buffer solution. A second aspect of the present disclosure relates to a system for extracorporeal blood treatment, likewise using said buffer solution and the apparatus, and furthermore to a treatment apparatus for extracorporeal blood treatment comprising the aforementioned system.

Abstract: The present disclosure relates to various aspects of a procedure for reducing the carbon dioxide content in blood during the treatment of patients. A first aspect of the present disclosure relates to a buffer solution for use in reducing the carbon dioxide content in the blood when treating a patient suffering from pulmonary insufficiency or the complete failure of lung function, wherein the fluid is in gas exchange with a portion of the patient's blood conducted through an extracorporeal circuit. The first aspect of the present disclosure further relates to an apparatus for the extracorporeal reduction of the carbon dioxide content in the blood using said buffer solution. A second aspect of the present disclosure relates to a system for extracorporeal blood treatment, likewise using said buffer solution and the apparatus, and furthermore to a treatment apparatus for extracorporeal blood treatment comprising the aforementioned system.

Abstract: The present invention relates to the use of a tri-substituted glycerol compound for the manufacture of a medicament for the treatment of hematological malignancies. The invention also refers to a kit-of-parts comprising such a medicament. Finally, the invention also relates to a corresponding method for the treatment of such conditions as well as to an in vitro method for determining the susceptibility of such malignant cells to a medicament as defined in the invention.

Abstract: The invention relates to a method for purifying mesenchymal stem cells, producing cells corresponding to prior art, the cells obtained being characterised by an increased proliferation capacity while maintaining the multipotency and typical antigen characteristics. To this end, mesenchymal stem cells that can be multiplied in a significantly improved manner compared to prior art are first provided and can also be differentiated, after a longer cultivation period, in three mesenchymal directions.

Abstract: In order to be able still more precisely to determine the blood clotting activity in a patient according to the invention there is provided a method of extracorporeal determination of the blood clotting activity of a blood sample of an individual, in which the clotting time which elapses until the blood sample reaches a given degree of clotting or the degree of clotting reached by the blood sample within a given time is measured or in which in a corresponding manner the fibrinolysis time or the degree of fibrinolysis of a blood sample which has previously clotted to a certain degree is measured, the method being characterised in that measurement of the clotting/fibrinolysis time or the degree of clotting/fibrinolysis is effected with the exclusion of air.

Abstract: The present invention relates to the use of a tri-substituted glycerol compound for the manufacture of a medicament for the treatment of hematological malignancies. The invention also refers to a kit-of-parts comprising such a medicament. Finally, the invention also relates to a corresponding method for the treatment of such conditions as well as to an in vitro method for determining the susceptibility of such malignant cells to a medicament as defined in the invention.

Abstract: An aqueous solution of gelatin used as a flushing liquid for blood cells, in particular erythrocytes, in order to give no changes in the blood cells or at most slight, quality-impairing changes.

Abstract: An apparatus is provided for oxygenating a patient, comprising an oxygen supply means with an oxygen applicator for supplying oxygen via the nose, the oxygen applicator being a closed system, with the applicator affixable about the nose in a tightly-sealable manner so that it supplies pure oxygen solely via the nose in a directed flow, and additionally comprising a one-way valve which can be inserted in substantially sealing-tight manner into the mouth of the patient, the one-way valve opening only upon gas outflow out of the mouth, the closed system at all times having a pressure which is greater than the pressure necessary to open the one-way valve, such that respired air from the patient can escape only through the mouth and no air can escape through the nose.

Abstract: A sterilizable aqueous solution with substantially physiological values of the pH, bicarbonate concentration and CO.sub.2 partial pressure, as well as with metabolizable anions in the form of two separately stored single solutions, which are combined with one another prior to use and whereof one is a bicarbonate-free, acid solution and the other a bicarbonate-containing, alkaline solution, is characterized in that per liter of the finished solution obtained by combining the two single solutions, the acid single solution contains 7.3 mmole.+-.3% of at least one metabolizable, organic acid and the alkaline single solution 19.1 mmole.+-.3% of alkali bicarbonate and 6.1 mmole.+-.3% of alkali carbonate.

Abstract: In order to simplify the operation for determination of the acid-base status of blood, composed of the values for pH, pCO.sub.2 and the base excess BE, the base excess BE is determined through measurement of the pH-value at a pCO.sub.2 of about 0 mn Hg. The pH-values may be determined photometrically, in which case the indicator solution for measuring the actual blood-pH is an aqueous solution of 40 micromol/l bromthymol blue plus 0.2 g/l sodium dodecylsulfate plus 1% ethanol; and for measurement of the base excess BE is an aqueous solution of 65 micro mol/l naphtholphthalein plus 0.2 g/l sodium dodecylsulfate plus 15% dimethylsulfoxide, which are measured at a wavelength of 635 nm. If desired, one may use a single solution for measuring both actual blood-pH as well as the base excess BE, composed of 16 micromol/l bromthymol blue plus 34 micromol/l naphtholphthalein plus 0.15 g/l sodium dodecylsulfate, which is measured at 615 nm wavelength.

Abstract: In order to simplify the operation for determination of the acid-base status of blood, composed of the values for pH, pCO.sub.2 and the base excess BE, the base excess BE is determined through measurement of the pH-value at a pCO.sub.2 of about 0 mm Hg. The pH-values may be determined photometrically, in which case the indicator solution for measuring the actual blood-pH is an aqueous solution of 40 micromol/l bromthymol blue plus 0.2 g/l sodium dodecylsulfate plus 1% ethanol; and for measurement of the base excess BE is an aqueous solution of 65 micro mol/l naphtholphthalein plus 0.2 g/l sodium dodecylsulfate plus 15% dimethylsulfoxide, which are measured at a wavelength of 635 nm. If desired, one may use a single solution for measuring both actual blood-pH as well as the base excess BE, composed of 16 micromol/l bromthymol blue plus 34 micromol/l naphtholphthalein plus 0.15 g/l sodium dodecylsulfate, which is measured at 615 nm wavelength.

Abstract: A reagent for photometric determination of the hemoglobin content of blood, which produces a characteristic color upon addition of the blood sample, consisting of an aqueous alkaline solution comprising a water-soluble, non-ionic detergent, whereby all hemoglobin-derivatives occurring in the blood and hemederivatives are converted into a unitary end product having a distinct absorption maximum in the visible spectral range.